태변흡인증후군에서 폐표면활성제 사용이 호흡기지표에 미치는 영향에 대한 체계적 문헌고찰과 메타분석
The Effect on Pulmonary Indices of Surfactant Therapy for Meconium Aspiration Syndrome: Systematic Review and Meta-analysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 최근 폐표면활성제는 태변흡인증후군 환자에서 호흡곤란을 호전시키기 위한 치료 중 하나로 사용되고 있다. 본 연구에서는 태변흡인증후군에서 폐표면활성제가 치료결과로서 호흡기지표에 미치는 영향을 살펴보았다. 방법: MEDLINE, EMBASE, CENTRAL 등의 주요 데이터베이스 및 초록 등을 검색하여 2011년 6월까지 보고된 관련 무작위배정연구를 선별하였다. OI 또는 a/A PO_2와 같은 호흡기 지표를포함한 자료를 추출하여 폐표면활성제 보충요법과 폐표면활성제 세정요법 각각에 대해 메타분석을 수행하였다. 비뚤림 위험및 임상적, 통계적 이질성을 평가하였다. 결과: 두 건의 폐표면활성제 보충요법 연구와 두 건의 폐표면활성제 세정요법 연구가 분석에 포함되었다. 폐표면활성제 보충요법의 경우 OI에서는 두 연구 결과 사이의 이질성이 큰 반면, a/A PO_2에서는 보충요법 후 시간이 경과할 수록 군 간의 차이가유의하게 나타났다(12시간째 WMD 0.08, 95% CI 0.04, 0.12; 24시간째 WMD 0.17, 95% CI 0.06, 0.28). 폐표면활성제 세정요법의 경우 통합하여 분석하였을 때 치료군이 대조군에 비해 임상경과가 좋은 경향을 보였으나 통계적인 유의성은 확보하지는 못하였다. 결론: 태변흡인증후군에서 폐표면활성제 사용은 임상경과를호전시키는 것으로 보인다. 기존의 연구수가 제한되어 있고 대상환자의 중증도 및 폐표면활성제 투여방법 또한 서로 다르므로 추가적인 연구를 통한 보충적인 근거가 도움이 될 것이다.
Abstract
Purpose: Surfactants have been used to improve oxygenation for infants with meconium aspiration syndrome (MAS). We evaluated the change of pulmonary indices after surfactant therapy for MAS through a systematic meta-analysis. Methods: Relevant randomized controlled studies (RCTs) were identified by database searches in MEDLINE, EMBASE, and CENTRAL,up to June 2011, and by additional hand searches. Data were extracted regarding pulmonary indices, such as the oxygen index and arterial alveolar oxygen gradient. Meta-analyses were separately conducted for the studies of surfactant lavage therapy and surfactant bolus therapy. The risk of bias was assessed, and clinical as well as statistical heterogeneities were also investigated. Results: Two RCTs for bolus surfactant therapy and two RCTs for surfactant lavage therapy were identified. The oxygenation index results were heterogeneous between the two studies in which bolus surfactant therapy was given, while a/A PO_2 showed significantly better results in the treatment group over time after use of surfactant (12 hours: WMD 0.08, 95% CI 0.04-0.12; 24 hours:WMD 0.17, 95% CI 0.06-0.28). For surfactant lavage therapy, both studies consistently suggested an interventional benefit in terms of the pulmonary indices although it did not reach statistical significance. Conclusion: Surfactant therapy appeared to improve oxygenation of infants with MAS. Since a limited number of RCTs are available in the current literature and those studies were also clinically heterogeneous in terms of illness severity and the method of surfactant use, further research is needed to gather evidence to support surfactant therapy in MAS.
참고문헌 (20)
- Kim DY, "Frequency and clinical outcome of the respiratory tract disease in full-term infant", J Korean Soc Neonatol, 14, pp.199~205 (2007)
- Davey AM, "Meconium aspiration syndrome: physiological and inflammatory changes in a newborn piglet model", Pediatr Pulmonol, 16, pp.101~108 (1993)
- Bae CW, "Morphology and function of pulmonary surfactant inhibited by meconium", Pediatr Res, 44, pp.187~191 (1998)
- Cleary GM, "Meconium-stained amniotic fluid and the meconium aspiration syndrome. An update", Pediatr Clin North Am, 45, pp.511~529 (1998)
- Dargaville PA, "Surfactant therapy for meconium aspiration syndrome: current status", Drugs, 65, pp.2569~2591 (2005)
- El Shahed AI, "Surfactant for meconium aspiration syndrome in full term", near term infants, 2007, pp.(3), CD002054~
- Choi HJ, "Surfactant lavage therapy for meconium aspiration syndrome : a systematic review and meta-analysis", Neonatology, 101, pp.183~191 (2011)
- Trachsel D, "Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure", Am J Respir Crit Care Med, 172, pp.206~211 (2005)
- 전지현, "미숙아 호흡 곤란 증후군에서 호흡 중증도 지표로서의oxygenation index", Korean Journal of Pediatrics, 51(2), pp.145~149 (2008), 대한소아과학회
- Hall RT, "Indications for surfactant therapy--the aAPO2 coming of age", Pediatrics, 103, pp.E25~ (1999)
- "Cochrane handbook for systematic reviews of interventions Version 5.0.2 (updated September 2009)"[URL]
- "Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial", Acta Paediatr, 94, pp.896~902 (2005), Chinese Collaborative Study Group for Neonatal Respiratory Diseases
- Findlay RD, "Surfactant replacement therapy for meconium aspiration syndrome", Pediatrics, 97, pp.48~52 (1996)
- Wiswell TE, "A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome", Pediatrics, 109, pp.1081~1087 (2002)
- Dargaville PA, "Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndrome", J Pediatr, 158, pp.383~389 (2011)
- Lotze A, "Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure", J Pediatr, 132, pp.40~47 (1998)
- Cleary GM, "Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration", Pediatrics, 100, pp.998~1003 (1997)
- Fuchimukai T, "Artificial pulmonary surfactant inhibited by proteins", J Appl Physiol, 62, pp.429~437 (1987)
- Roberts JD Jr, "Inhaled nitric oxide and persistent pulmonary hypertension of the newborn", N Engl J Med, 336, pp.605~610 (1997)
- Park HK, "Comparison of treatment outcomes in persistent pulmonary hypertension of the newborn", J Korean Soc Neonatol, 10, pp.29~38 (2003)